Alexander V. Kulikov

Alexander V. Kulikov

Auto-generated profile, based on publicly available information

Alexander V. Kulikov

Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
AKAlexander V. Kulikov
Alexander V. Kulikov
Maria A TikhonovaMaria A Tikhonova
Maria A Tikhonova
VKVictor A. Kulikov
Victor A. Kulikov

1 January 2005 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
AKAlexander V. Kulikov
Alexander V. Kulikov
VNVladimir S. Naumenko
Vladimir S. Naumenko
IVIrina P. Voronova
Irina P. Voronova
Maria A TikhonovaMaria A Tikhonova
Maria A Tikhonova
NPNina K. Popova
Nina K. Popova

9 May 2005 in Genes, Brain and Behavior
Verified
Journal Article
Closed access
PDF file
AKA. V. Kulikov
A. V. Kulikov
DOD. V. Osipova
D. V. Osipova
VNV. S. Naumenko
V. S. Naumenko
NPN. K. Popova
N. K. Popova

11 November 2008 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
DODaria V. Osipova
Daria V. Osipova
AKAlexander V. Kulikov
Alexander V. Kulikov
NPNina K. Popova
Nina K. Popova

1 September 2014 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
VKVictor A. Kulikov
Victor A. Kulikov
NKNikita V. Khotskin
Nikita V. Khotskin
SNSergey V. Nikitin
Sergey V. Nikitin
VLVasily S. Lankin
Vasily S. Lankin
AKAlexander V. Kulikov
Alexander V. Kulikov
OTOleg V. Trapezov
Oleg V. Trapezov

2 July 2019 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
EKElizabeth A. Kulikova
Elizabeth A. Kulikova
AKAlexander V. Kulikov
Alexander V. Kulikov
Introduction: Tryptophan hydroxylase 2 (TPH2) is the key, rate-limiting enzyme of serotonin (5-HT) synthesis in the brain. Some polymorphic variants of the human Tph2 gene are associated with psychiatric disorders. Area covered: This review focuses on the mechanisms underlying the association between the TPH2 activity and behavioral disturbances in models of psychiatric disorders. Specifically, it discusses: 1) genetic and posttranslational mechanisms defining the TPH2 activity, 2) behavioral effects of knockout and loss-of-function mutations in the mouse Tph2 gene, 3) pharmacological inhibition and the activation of the TPH2 activity and 4) alterations in the brain TPH2 activity in animal models of psychiatric disorders. We show the dual role of the TPH2 activity: both deficit and excess of the TPH2 activity cause significant behavioral disturbances in animal models of depression, anxiety, aggression, obsessive compulsive disorders, schizophrenia and catalepsy. Expert opinion: Pharmacological chaperones correcting the structure of the TPH2 molecule are promising tools for treatment of some hereditary psychiatric disorders caused by loss-of-function mutations in the human Tph2 gene; while some stress-induced affective disorders, associated with the elevated TPH2 activity, may be effectively treated by TPH2 inhibitors. This dual role of TPH2 should be taken into consideration during therapy of psychiatric disorders.